{"id":666356,"date":"2023-09-05T16:58:01","date_gmt":"2023-09-05T16:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=666356"},"modified":"2023-09-05T16:58:01","modified_gmt":"2023-09-05T16:58:01","slug":"delveinsight-highlights-major-advances-transformative-therapies-and-9-leading-players-wheeling-the-advanced-nonsquamous-squamous-nsclc-clinical-trial-pipeline-landscape","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/delveinsight-highlights-major-advances-transformative-therapies-and-9-leading-players-wheeling-the-advanced-nonsquamous-squamous-nsclc-clinical-trial-pipeline-landscape_666356.html","title":{"rendered":"DelveInsight Highlights Major Advances, Transformative Therapies, and 9+ Leading Players Wheeling the Advanced Non-Squamous &#038; Squamous NSCLC Clinical Trial Pipeline Landscape"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1693909683.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"DelveInsight Highlights Major Advances, Transformative Therapies, and 9+ Leading Players Wheeling the Advanced Non-Squamous &amp; Squamous NSCLC Clinical Trial Pipeline Landscape\" src=\"https:\/\/www.abnewswire.com\/uploads\/1693909683.png\" alt=\"DelveInsight Highlights Major Advances, Transformative Therapies, and 9+ Leading Players Wheeling the Advanced Non-Squamous &amp; Squamous NSCLC Clinical Trial Pipeline Landscape\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">The Advanced Non-Squamous &amp; Squamous NSCLC Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Advanced Non-Squamous &amp; Squamous NSCLC treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Advanced Non-Squamous &amp; Squamous NSCLC pipeline landscape and fostering the potential growth of Advanced Non-Squamous &amp; Squamous NSCLC therapeutic advancements.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Advanced Non-Squamous &amp; Squamous NSCLC Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s Advanced Non-Squamous &amp; Squamous NSCLC pipeline report depicts a robust space with 9+ active players working to develop 10+ pipeline therapies for Advanced Non-Squamous &amp; Squamous NSCLC treatment.<\/li>\n<li>The leading companies working in the Advanced Non-Squamous &amp; Squamous NSCLC market include <em><strong>Jiangsu Alphamab Biopharmaceuticals, Jiangsu HengRui Medicine, Daiichi Sankyo Company, Genentech, Sinocelltech, Merck KGaA, Mirati Therapeutics, Ability Pharmaceuticals, Axelar AB<\/strong><\/em>, and others.<\/li>\n<li>Promising Advanced Non-Squamous &amp; Squamous NSCLC Pipeline Therapies in the various stages of development include <em><strong>Pyrotinib, Docetaxel, Tiragolumab, Atezolizumab, Bevacizumab, Pemetrexed, TQB2450 Injection, Cisplatin (or carboplatin), Bevacizumab-Pfizer, Carboplatin, Paclitaxel, PM8002, T-DXd, Amivantamab, Lazertinib, Zirabev<\/strong><\/em>, and others.<\/li>\n<li>On March 2023, Jiangsu HengRui Medicine Co., Ltd. announced a study of Phase 3 Clinical Trials for Pyrotinib and Docetaxel. This is a randomized, positive-controlled, open-label, international multicenter, Phase 3 clinical study to compare the efficacy and safety of pyrotinib versus docetaxel in patients with advanced non-squamous NSCLC harboring a HER2 exon 20 mutation who failed platinum based chemotherapy.<\/li>\n<li>On May 2023, Georgetown University announced a study of Phase 2 Clinical Trials for Tiragolumab, Atezolizumab, and Bevacizumab. To evaluate the efficacy of tiragolumab with atezolizumab and bevacizumab in previously-treated advanced non-squamous NSCLC.<\/li>\n<li>On May 2023, BeiGene announced a study of Phase 3 Clinical Trials for Tislelizumab,Cisplatin or Carboplatin ,Pemetrexed. A Phase 3, Open-Label, Multi-Center, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Participants With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer. 45 sites will be involved in China, 320 subjects will be enrolled.<\/li>\n<li>On July 2023, Biotheus Inc. announced a study of Phase 2 &amp; 3 Clinical Trials for PM8002 and Carboplatin. PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II\/III study to evaluate the efficacy and safety of PM8002 in combination with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have failed to EGFR-TKI treatment.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in Advanced Non-Squamous &amp; Squamous NSCLC Treatment Drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/advanced-non-squamous-and-squamous-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Advanced Non-Squamous &amp; Squamous NSCLC Infection Pipeline Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">The Advanced Non-Squamous &amp; Squamous NSCLC pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Non-Squamous &amp; Squamous NSCLC drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Non-Squamous &amp; Squamous NSCLC clinical trial landscape.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Advanced Non-Squamous &amp; Squamous NSCLC Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Lung cancer is one of the most common types of cancer across the globe and among the leading causes of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers and is further classified into squamous NSCLC and non-squamous NSCLC (includes large cell histologies and adenocarcinoma).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Find out more about Advanced Non-Squamous &amp; Squamous NSCLC Treatment Drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/advanced-non-squamous-and-squamous-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Drugs for Advanced Non-Squamous &amp; Squamous NSCLC Treatment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Advanced Non-Squamous &amp; Squamous NSCLC Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>KN-046: Jiangsu Alphamab Biopharmaceuticals<\/li>\n<li>Pyrotinib: Jiangsu HengRui Medicine<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Advanced Non-Squamous &amp; Squamous NSCLC Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 9+ key companies which are developing the therapies for Advanced Non-Squamous &amp; Squamous NSCLC. The Advanced Non-Squamous &amp; Squamous NSCLC companies which have their Advanced Non-Squamous &amp; Squamous NSCLC drug candidates in the most advanced stage, i.e. phase II include, Jiangsu Alphamab Biopharmaceuticals.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the emerging Advanced Non-Squamous &amp; Squamous NSCLC Pipeline Therapies @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/advanced-non-squamous-and-squamous-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Advanced Non-Squamous &amp; Squamous NSCLC Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Advanced Non-Squamous &amp; Squamous NSCLC Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC Companies- Jiangsu Alphamab Biopharmaceuticals, Jiangsu HengRui Medicine, Daiichi Sankyo Company, Genentech, Sinocelltech, Merck KGaA, Mirati Therapeutics, Ability Pharmaceuticals, Axelar AB, and others.<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC Pipeline Therapies- Pyrotinib, Docetaxel, Tiragolumab, Atezolizumab, Bevacizumab, Pemetrexed, TQB2450 Injection, Cisplatin (or carboplatin), Bevacizumab-Pfizer, Carboplatin, Paclitaxel, PM8002, T-DXd, Amivantamab, Lazertinib, Zirabev, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for new drugs for Advanced Non-Squamous &amp; Squamous NSCLC Treatment, Visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/advanced-non-squamous-and-squamous-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Advanced Non-Squamous &amp; Squamous NSCLC Market Drivers and Barriers, and Future Perspective<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Preregistration)<\/li>\n<li>KN-046: Jiangsu Alphamab Biopharmaceuticals<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Zuranolone: SAGE Therapeutics<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I\/II)<\/li>\n<li>ABTL0812: Ability Pharmaceuticals<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC Key Companies<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC Key Products<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC- Unmet Needs<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC- Market Drivers and Barriers<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC- Future Perspectives and Conclusion<\/li>\n<li>Advanced Non-Squamous &amp; Squamous NSCLC Analyst Views<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For further information on the Advanced Non-Squamous &amp; Squamous NSCLC pipeline therapeutics, reach out to <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/advanced-non-squamous-and-squamous-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Advanced Non-Squamous &amp; Squamous NSCLC Unmet Needs and Analyst Views<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=delveinsight-highlights-major-advances-transformative-therapies-and-9-leading-players-wheeling-the-advanced-nonsquamous-squamous-nsclc-clinical-trial-pipeline-landscape\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=delveinsight-highlights-major-advances-transformative-therapies-and-9-leading-players-wheeling-the-advanced-nonsquamous-squamous-nsclc-clinical-trial-pipeline-landscape\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Advanced Non-Squamous &amp; Squamous NSCLC Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Advanced Non-Squamous &amp; Squamous NSCLC treatments, including those already in the market, as well as those in different phases of clinical development. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/delveinsight-highlights-major-advances-transformative-therapies-and-9-leading-players-wheeling-the-advanced-nonsquamous-squamous-nsclc-clinical-trial-pipeline-landscape_666356.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-666356","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/666356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=666356"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/666356\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=666356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=666356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=666356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}